Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>
Barbara A. Spruce(University of Dundee), Suzanne A. Eccles(Discovery Centre), Alastair M. Thompson(Baylor College of Medicine), Michelle Ferguson(Ninewells Hospital), Michelle A. Cooper(University of Dundee), Doris McLean(University of Dundee), Florence I. Raynaud(Institute of Cancer Research), Angela Hayes(Institute of Cancer Research), John A. Peters(University of Dundee), Jayne Samson(University of Dundee), Bernard Nutley(Institute of Cancer Research), Nicholas R. Leslie(University of Dundee), N. McTavish(University of Dundee), M. Virginia L. Appleyard(University of Dundee), Jeremy J. Lambert(Ninewells Hospital), C. Peter Downes(University of Dundee), Lorna Campbell(University of Dundee), J. W. Howie(University of Dundee), Gary Box(Institute of Cancer Research), Stephen A. Watt(University of Dundee), Mary O’Neill(University of Dundee), Stephen T. Safrany(University of Dundee), Karen Murray(University of Dundee), Alan R. Prescott(University of Dundee)
Cited by 165
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation
|BMC Biology|2012|1k
Neurosteroids and GABAA receptor function
|Trends in Pharmacological Sciences|1995|743
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors
|British Journal of Pharmacology|2019|712
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
|British Journal of Pharmacology|2017|597